The development of MTHFD2 inhibitors could present a new promising therapeutic strategy for MTHFD2‐overexpressing cancers with minimal side effects.[14] Although MTHFD2 is exclusively expressed in cancer cells, a close homolog known as MTHFD1 which shares 36.4 % sequence identity and 53.6 % sequence similarity with MTHFD2, is present in healthy adult tissue,[15] thus raising selectivity concerns in the development of MTHFD2 inhibitors. This evidence concerns the gene MTHFD1 and cancer.